The limitations of our study include the use of three single-gene assays for EGFR, ALK, and ROS-1, a current reality in our public system, in comparison to the growing practice of broader NGS testing for multiple targets now relevant in the care of advanced NSCLC patients (Figure 5, [41]). Here, EGFR is linked to non-small cell lung carcinoma.